CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
+43.14%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$1.36B
AUM Growth
+$1.36B
(-15%)
Cap. Flow
-$54.8M
Cap. Flow
% of AUM
-4.02%
Top 10 Holdings %
Top 10 Hldgs %
69.81%
Holding
40
New
4
Increased
10
Reduced
8
Closed
9
Top Buys
| 1 |
Vaxcyte
PCVX
|
$57.7M |
| 2 |
Nuvalent
NUVL
|
$53.4M |
| 3 |
Scholar Rock
SRRK
|
$41.1M |
| 4 |
Nurix Therapeutics
NRIX
|
$25.4M |
| 5 |
Cardiff Oncology
CRDF
|
$23.4M |
Top Sells
| 1 |
Celldex Therapeutics
CLDX
|
$55M |
| 2 |
Perspective Therapeutics
CATX
|
$44.7M |
| 3 |
Kura Oncology
KURA
|
$35.2M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
$34.1M |
| 5 |
Arvinas
ARVN
|
$29.6M |
Sector Composition
| 1 | Healthcare | 99.44% |
| 2 | Financials | 0.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Merus
MRUS
$4.98B
| $163M | 11.94% | 3,874,182 +524,182 | +16% | +$22M |
|
|
2
Vaxcyte
PCVX
$4B
| $133M | 9.75% | 1,625,000 +705,000 | +77% | +$57.7M |
|
|
3
Nuvalent
NUVL
$5.52B
| $127M | 9.3% | 1,621,600 +681,600 | +73% | +$53.4M |
|
4
Xenon Pharmaceuticals
XENE
$2.98B
| $107M | 7.87% | 2,740,000 +40,000 | +1% | +$1.57M |
|
5
Enliven Therapeutics
ELVN
$1.2B
| $94.6M | 6.93% | 4,205,000 +105,000 | +3% | +$2.36M |
|
6
Vera Therapeutics
VERA
$1.38B
| $82.8M | 6.07% | 1,958,600 -516,400 | -21% | -$21.8M |
|
7
Soleno Therapeutics
SLNO
$3.6B
| $68.5M | 5.02% | 1,525,000 +265,000 | +21% | +$11.9M |
|
8
Alkermes
ALKS
$4.78B
| $66.1M | 4.85% | 2,300,000 -600,000 | -21% | -$17.3M |
|
|
9
Nurix Therapeutics
NRIX
$714M
| $56.5M | 4.14% | 3,000,000 +1,350,000 | +82% | +$25.4M |
|
10
Cogent Biosciences
COGT
$1.69B
| $53.7M | 3.93% | 6,881,629 -658,301 | -9% | -$5.13M |
|
11
Spyre Therapeutics
SYRE
$996M
| $46.3M | 3.39% | 1,988,084 | – | – |
|
12
Viridian Therapeutics
VRDN
$1.5B
| $46M | 3.37% | 2,400,000 -150,124 | -6% | -$2.88M |
|
|
13
Scholar Rock
SRRK
$3.14B
| $41.1M | 3.01% | +950,000 | New | +$41.1M |
|
|
CNTA
14
Centessa Pharmaceuticals
CNTA
$2.25B
| $37.2M | 2.72% | 2,218,425 +868,425 | +64% | +$14.5M |
|
15
Pharvaris
PHVS
$1.39B
| $36.6M | 2.69% | 1,911,433 | – | – |
|
16
MindMed
MNMD
$676M
| $30M | 2.2% | 4,308,425 -3,691,575 | -46% | -$25.7M |
|
|
ORKA
17
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $27.5M | 2.02% | 1,419,714 +50,000 | +4% | +$970K |
|
|
18
Cardiff Oncology
CRDF
$140M
| $23.4M | 1.71% | +5,384,616 | New | +$23.4M |
|
19
Inhibikase Therapeutics
IKT
$134M
| $19.3M | 1.41% | +5,925,000 | New | +$19.3M |
|
20
Neurogene
NGNE
$264M
| $18.3M | 1.34% | 800,000 +600,000 | +300% | +$13.7M |
|
|
DRUG
21
Bright Minds Biosciences
DRUG
$276M
| $18M | 1.32% | +500,000 | New | +$18M |
|
22
Oric Pharmaceuticals
ORIC
$994M
| $16.1M | 1.18% | 2,000,000 | – | – |
|
23
Apogee Therapeutics
APGE
$2.17B
| $13.1M | 0.96% | 290,000 | – | – |
|
|
ABVX
24
Abivax
ABVX
$6.12B
| $9.4M | 0.69% | 1,284,110 | – | – |
|
|
PCSC
25
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $7.64M | 0.56% | 750,000 | – | – |
|